Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2014

Open Access 01-12-2014 | Research

Divergent effects of muscarinic receptor subtype gene ablation on murine colon tumorigenesis reveals association of M3R and zinc finger protein 277 expression in colon neoplasia

Authors: Kunrong Cheng, Guofeng Xie, Sandeep Khurana, Jonathon Heath, Cinthia B Drachenberg, Jennifer Timmons, Nirish Shah, Jean-Pierre Raufman

Published in: Molecular Cancer | Issue 1/2014

Login to get access

Abstract

Background

M3 and M1 subtype muscarinic receptors are co-expressed in normal and neoplastic intestinal epithelial cells. In mice, ablating Chrm3, the gene encoding M3R, robustly attenuates intestinal tumor formation. Here we investigated the effects of Chrm1 gene ablation, alone and in combination with Chrm3 ablation.

Methods

We used wild-type, Chrm1 -/- , Chrm3 -/- and combined Chrm1 -/- /Chrm3 -/- knockout (dual knockout) mice. Animals were treated with azoxymethane, an intestine-selective carcinogen. After 20 weeks, colon tumors were counted and analyzed histologically and by immunohistochemical staining. Tumor gene expression was analyzed using microarray and results validated by RT-PCR. Key findings were extended by analyzing gene and protein expression in human colon cancers and adjacent normal colon tissue.

Results

Azoxymethane-treated Chrm3 -/- mice had fewer and smaller colon tumors than wild-type mice. Reductions in colon tumor number and size were not observed in Chrm1 -/- or dual knockout mice. To gain genetic insight into these divergent phenotypes we used an unbiased microarray approach to compare gene expression in tumors from Chrm3 -/- to those in wild-type mice. We detected altered expression of 430 genes, validated by quantitative RT-PCR for the top 14 up- and 14 down-regulated genes. Comparing expression of this 28-gene subset in tumors from wild-type, Chrm3 -/- , Chrm1 -/- and dual knockout mice revealed significantly reduced expression of Zfp277, encoding zinc finger protein 277, in tissue from M3R-deficient and dual knockout mice, and parallel changes in Zfp277 protein expression. Notably, mRNA and protein for ZNF277, the human analogue of Zfp277, were increased in human colon cancer compared to adjacent normal colon, along with parallel changes in expression of M3R.

Conclusions

Our results identify a novel candidate mouse gene, Zfp277, whose expression pattern is compatible with a role in mediating divergent effects of Chrm3 and Chrm1 gene ablation on murine intestinal neoplasia. The biological importance of this observation is strengthened by finding increased expression of ZNF277 in human colon cancer with a parallel increase in M3R expression. The role of zinc finger protein 277 in colon cancer and its relationship to M3R expression and activation are worthy of further investigation.
Appendix
Available only for authorised users
Literature
1.
Song P, Sekhon HS, Jia Y, Keller JA, Blusztajn JK, Mark GP, Spindel ER: Acetylcholine is synthesized by and acts as an autocrine growth factor for small cell lung carcinoma. Cancer Res. 2003, 63: 214-221.PubMed
2.
Song P, Sekhon HS, Lu A, Arredondo J, Sauer D, Gravett C, Mark GP, Grando SA, Spindel ER: M3 muscarinic receptor antagonists inhibit small cell lung carcinoma growth and mitogen-activated protein kinase phosphorylation induced by acetylcholine secretion. Cancer Res. 2007, 67: 3936-3944. 10.1158/0008-5472.CAN-06-2484CrossRefPubMed
3.
Jimenez E, Montiel M: Activation of MAP kinase by muscarinic cholinergic receptors induces cell proliferation and protein synthesis in human breast cancer cells. J Cell Physiol. 2005, 204: 678-686. 10.1002/jcp.20326CrossRefPubMed
4.
Rimmaudo LE, de la Torre E, Sacerdote de Lustig E, Sales ME: Muscarinic receptors are involved in LMM3 tumor cells proliferation and angiogenesis. Biochem Biophys Res Commun. 2005, 334: 1359-1364. 10.1016/j.bbrc.2005.07.031CrossRefPubMed
5.
Rayford W, Noble MJ, Austenfeld MA, Weigel J, Mebust WK, Shah GV: Muscarinic cholinergic receptors promote growth of human prostate cancer cells. Prostate. 1997, 30: 160-166. 10.1002/(SICI)1097-0045(19970215)30:3<160::AID-PROS3>3.0.CO;2-QCrossRefPubMed
6.
Cheng K, Zimniak P, Raufman JP: Transactivation of the epidermal growth factor receptor mediates cholinergic agonist-induced proliferation of H508 human colon cancer cells. Cancer Res. 2003, 63: 6744-6750.PubMed
7.
Ukegawa JI, Takeuchi Y, Kusayanagi S, Mitamura K: Growth-promoting effect of muscarinic acetylcholine receptors in colon cancer cells. J Cancer Res Clin Oncol. 2003, 129: 272-278.PubMed
8.
Boss A, Oppitz M, Lippert G, Drews U: Muscarinic cholinergic receptors in the human melanoma cell line SK-Mel 28: modulation of chemotaxis. Clin Exp Dermatol. 2005, 30: 557-564. 10.1111/j.1365-2230.2005.01865.xCrossRefPubMed
9.
10.
Wess J: Molecular biology of muscarinic acetylcholine receptors. Crit Rev Neurobiol. 1996, 10: 69-99. 10.1615/CritRevNeurobiol.v10.i1.40CrossRefPubMed
11.
Cheng K, Samimi R, Xie G, Shant J, Drachenberg C, Wade M, Davis RJ, Nomikos G, Raufman JP: Acetylcholine release by human colon cancer cells mediates autocrine stimulation of cell proliferation. Am J Physiol Gastrointest Liver Physiol. 2008, 295: G591-G597. 10.1152/ajpgi.00055.2008PubMedCentralCrossRefPubMed
12.
Shant J, Cheng K, Marasa BS, Wang JY, Raufman JP: Akt-dependent NF-kappaB activation is required for bile acids to rescue colon cancer cells from stress-induced apoptosis. Exp Cell Res. 2009, 315: 432-450. 10.1016/j.yexcr.2008.11.003PubMedCentralCrossRefPubMed
13.
Belo A, Cheng K, Chahdi A, Shant J, Xie G, Khurana S, Raufman JP: Muscarinic receptor agonists stimulate human colon cancer cell migration and invasion. Am J Physiol Gastrointest Liver Physiol. 2011, 300: G749-G760. 10.1152/ajpgi.00306.2010PubMedCentralCrossRefPubMed
14.
Raufman JP, Cheng K, Saxena N, Chahdi A, Belo A, Khurana S, Xie G: Muscarinic receptor agonists stimulate matrix metalloproteinase 1-dependent invasion of human colon cancer cells. Biochem Biophys Res Commun. 2011, 415: 319-324. 10.1016/j.bbrc.2011.10.052PubMedCentralCrossRefPubMed
15.
Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell. 2011, 144: 646-674. 10.1016/j.cell.2011.02.013CrossRefPubMed
16.
Wess J: Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications. Annu Rev Pharmacol Toxicol. 2004, 44: 423-450. 10.1146/annurev.pharmtox.44.101802.121622CrossRefPubMed
17.
Wess J, Eglen RM, Gautam D: Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat Rev Drug Discov. 2007, 6: 721-733. 10.1038/nrd2379CrossRefPubMed
18.
Wess J: Novel muscarinic receptor mutant mouse models. Handb Exp Pharmacol. 2012, 208: 95-117. 10.1007/978-3-642-23274-9_6CrossRefPubMed
19.
Raufman JP, Samimi R, Shah N, Khurana S, Shant J, Drachenberg C, Xie G, Wess J, Cheng K: Genetic ablation of M3 muscarinic receptors attenuates murine colon epithelial cell proliferation and neoplasia. Cancer Res. 2008, 68: 3573-3578. 10.1158/0008-5472.CAN-07-6810PubMedCentralCrossRefPubMed
20.
Raufman JP, Shant J, Xie G, Cheng K, Gao XM, Shiu B, Shah N, Drachenberg CB, Heath J, Wess J, Khurana S: Muscarinic receptor subtype-3 gene ablation and scopolamine butylbromide treatment attenuate small intestinal neoplasia in Apcmin/+ mice. Carcinogenesis. 2011, 32: 1396-1402. 10.1093/carcin/bgr118PubMedCentralCrossRefPubMed
21.
Xie G, Drachenberg C, Yamada M, Wess J, Raufman JP: Cholinergic agonist-induced pepsinogen secretion from murine gastric chief cells is mediated by M1 and M3 muscarinic receptors. Am J Physiol Gastrointest Liver Physiol. 2005, 289: G521-G529. 10.1152/ajpgi.00105.2004CrossRefPubMed
22.
Rosemond E, Rossi M, McMillin SM, Scarselli M, Donaldson JG, Wess J: Regulation of M muscarinic receptor expression and function by transmembrane protein 147. Mol Pharmacol. 2011, 79: 251-261. 10.1124/mol.110.067363PubMedCentralCrossRefPubMed
23.
Yamada M, Miyakawa T, Duttaroy A, Yamanaka A, Moriguchi T, Makita R, Ogawa M, Chou CJ, Xia B, Crawley JN, Felder CC, Deng CX, Wess J: Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. Nature. 2001, 410: 207-212. 10.1038/35065604CrossRefPubMed
24.
Neufert C, Becker C, Neurath MF: An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat Protoc. 2007, 2: 1998-2004. 10.1038/nprot.2007.279CrossRefPubMed
25.
Markowitz SD, Bertagnolli MM: Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med. 2009, 361: 2449-2460. 10.1056/NEJMra0804588PubMedCentralCrossRefPubMed
26.
Fichera A, Little N, Jagadeeswaran S, Dougherty U, Sehdev A, Mustafi R, Cerda S, Yuan W, Khare S, Tretiakova M, Gong C, Tallerico M, Cohen G, Joseph L, Hart J, Turner JR, Bissonnette M: Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis. Cancer Res. 2007, 67: 827-835. 10.1158/0008-5472.CAN-05-3343PubMedCentralCrossRefPubMed
27.
Dougherty U, Cerasi D, Taylor I, Kocherginsky M, Tekin U, Badal S, Aluri L, Sehdev A, Cerda S, Mustafi R, Delgado J, Joseph L, Zhu H, Hart J, Threadgill D, Fichera A, Bissonnette M: Epidermal growth factor receptor is required for colonic tumor promotion by dietary fat in the azoxymethane/dextran sulfate sodium model: roles of transforming growth factor-{alpha} and PTGS2. Clin Cancer Res. 2009, 15: 6780-6789. 10.1158/1078-0432.CCR-09-1678PubMedCentralCrossRefPubMed
28.
Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994, 107: 1183-1188.PubMed
29.
Sinicrope FA, Lemoine M, Xi L, Lynch PM, Cleary KR, Shen Y, Frazier ML: Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. Gastroenterology. 1999, 117: 350-358. 10.1053/gast.1999.0029900350CrossRefPubMed
30.
Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM: Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 1996, 87: 803-809. 10.1016/S0092-8674(00)81988-1CrossRefPubMed
31.
Khamas A, Ishikawa T, Shimokawa K, Mogushi K, Iida S, Ishiguro M, Mizushima H, Tanaka H, Uetake H, Sugihara K: Screening for epigenetically masked genes in colorectal cancer Using 5-Aza-2′-deoxycytidine, microarray and gene expression profile. Cancer Genomics Proteomics. 2012, 9: 67-75.PubMed
32.
Liang H, Guo W, Nagarajan L: Chromosomal mapping and genomic organization of an evolutionarily conserved zinc finger gene ZNF277. Genomics. 2000, 66: 226-228. 10.1006/geno.2000.6198CrossRefPubMed
33.
Negishi M, Saraya A, Mochizuki S, Helin K, Koseki H, Iwama A: A novel zinc finger protein Zfp277 mediates transcriptional repression of the Ink4a/arf locus through polycomb repressive complex 1. PLoS One. 2010, 5: e12373- 10.1371/journal.pone.0012373PubMedCentralCrossRefPubMed
34.
Fisahn A, Yamada M, Duttaroy A, Gan JW, Deng CX, McBain CJ, Wess J: Muscarinic induction of hippocampal gamma oscillations requires coupling of the M1 receptor to two mixed cation currents. Neuron. 2002, 33: 615-624. 10.1016/S0896-6273(02)00587-1CrossRefPubMed
35.
Miyakawa T, Yamada M, Duttaroy A, Wess J: Hyperactivity and intact hippocampus-dependent learning in mice lacking the M1 muscarinic acetylcholine receptor. J Neurosci. 2001, 21: 5239-5250.PubMed
36.
Gautam D, Heard TS, Cui Y, Miller G, Bloodworth L, Wess J: Cholinergic stimulation of salivary secretion studied with M1 and M3 muscarinic receptor single- and double-knockout mice. Mol Pharmacol. 2004, 66: 260-267. 10.1124/mol.66.2.260CrossRefPubMed
37.
Inaba M, Kobayashi T, Tashiro T, Sakurai Y, Maruo K, Ohnishi Y, Ueyama Y, Nomura T: Evaluation of antitumor activity in a human breast tumor/nude mouse model with a special emphasis on treatment dose. Cancer. 1989, 64: 1577-1582. 10.1002/1097-0142(19891015)64:8<1577::AID-CNCR2820640803>3.0.CO;2-ICrossRefPubMed
38.
Boivin GP, Washington K, Yang K, Ward JM, Pretlow TP, Russell R, Besselsen DG, Godfrey VL, Doetschman T, Dove WF, Pitot HC, Halberg RB, Itzkowitz SH, Groden J, Coffey RJ: Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology. 2003, 124: 762-777. 10.1053/gast.2003.50094CrossRefPubMed
39.
Workman C, Jensen LJ, Jarmer H, Berka R, Gautier L, Nielser HB, Saxild HH, Nielsen C, Brunak S, Knudsen S: A new non-linear normalization method for reducing variability in DNA microarray experiments. Genome Biol. 2002, 3: research0048-PubMedCentralCrossRefPubMed
40.
Schmid R, Baum P, Ittrich C, Fundel-Clemens K, Huber W, Brors B, Eils R, Weith A, Mennerich D, Quast K: Comparison of normalization methods for Illumina BeadChip HumanHT-12 v3. BMC Genomics. 2010, 11: 349- 10.1186/1471-2164-11-349PubMedCentralCrossRefPubMed
41.
Dydensborg AB, Herring E, Auclair J, Tremblay E, Beaulieu JF: Normalizing genes for quantitative RT-PCR in differentiating human intestinal epithelial cells and adenocarcinomas of the colon. Am J Physiol Gastrointest Liver Physiol. 2006, 290: G1067-G1074.CrossRefPubMed
42.
Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008, 3: 1101-1108. 10.1038/nprot.2008.73CrossRefPubMed
Metadata
Title
Divergent effects of muscarinic receptor subtype gene ablation on murine colon tumorigenesis reveals association of M3R and zinc finger protein 277 expression in colon neoplasia
Authors
Kunrong Cheng
Guofeng Xie
Sandeep Khurana
Jonathon Heath
Cinthia B Drachenberg
Jennifer Timmons
Nirish Shah
Jean-Pierre Raufman
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2014
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-13-77

Other articles of this Issue 1/2014

Molecular Cancer 1/2014 Go to the issue

Research

miR-300 inhibits epithelial to mesenchymal transition and metastasis by targeting Twist in human epithelial cancer

Research

Transfection of poly(I:C) can induce reactive oxygen species-triggered apoptosis and interferon-β-mediated growth arrest in human renal cell carcinoma cells via innate adjuvant receptors and the 2-5A system

Research

Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death

Research

miR-193a-3p regulates the multi-drug resistance of bladder cancer by targeting the LOXL4 gene and the Oxidative Stress pathway

Research

Integrated analysis of microRNA and mRNA expression and association with HIF binding reveals the complexity of microRNA expression regulation under hypoxia

Research

Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits